Decreased CX3CR1 messenger RNA expression is an independent molecular biomarker of early and late mortality in critically ill patients

Critical Care

Volumn 20, Issue 1, 2016, Pages

  Friggeri, Arnaud ^a,b   Cazalis, Marie Angélique ^b   Pachot, Alexandre ^b   Cour, Martin ^b   Argaud, Laurent ^b   Allaouchiche, Bernard ^a   Floccard, Bernard ^c   Schmitt, Zoé ^d   Martin, Olivier ^c   Rimmelé, Thomas ^b,c   Fontaine Kesteloot, Oriane ^a   Page, Mathieu ^c   Piriou, Vincent ^a   Bohé, Julien ^a   Monneret, Guillaume ^b   Morisset, Stéphane ^b   Textoris, Julien ^b,c   Vallin, Hélène ^a,b   Blein, Sophie ^b   Maucort Boulch, Delphine ^c   Lepape, Alain ^a,b   Venet, Fabienne ^b   more..

^a CENTRE HOSPITALIER LYON SUD   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c UNIVERSITÉ LYON 1   (France)

^d CROIX ROUSSE HOSPITAL   (France)

Author keywords

Biomarker; CX3CR1 mRNA; Immunosuppression; Intensive care unit; Mortality; Prognosis; Transcriptomics

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; CHEMOKINE RECEPTOR CX3CR1; MESSENGER RNA; NORADRENALIN; BIOLOGICAL MARKER; CX3CR1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; FRANCE; GENE EXPRESSION; HUMAN; INTENSIVE CARE UNIT; LACTIC ACIDEMIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; BLOOD; COMPLICATION; CRITICAL ILLNESS; HOSPITAL MORTALITY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SURVIVOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; COHORT STUDIES; CRITICAL ILLNESS; CX3C CHEMOKINE RECEPTOR 1; FEMALE; FRANCE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; ROC CURVE; SHOCK, SEPTIC; SURVIVORS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84976394950     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-016-1362-x     Document Type: Article

References (32)

1. Power GS, Harrison DA. Why try to predict ICU outcomes? Curr Opin Crit Care. 2014;20(5):544-9.
2. Kahn JM. Predicting outcome in critical care: past, present and future. Curr Opin Crit Care. 2014;20(5):542-3.
3. Marini JJ, Vincent JL, Annane D. Critical care evidence-new directions. JAMA. 2015;313(9):893-4.
4. Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, et al. A genomic storm in critically injured humans. J Exp Med. 2011;208(13):2581-90.
5. Wong HR, Cvijanovich NZ, Allen GL, Thomas NJ, Freishtat RJ, Anas N, et al. Validation of a gene expression-based subclassification strategy for pediatric septic shock. Crit Care Med. 2011;39(11):2511-7.
6. Cazalis MA, Lepape A, Venet F, Frager F, Mougin B, Vallin H, et al. Early and dynamic changes in gene expression in septic shock patients: a genome-wide approach. Intensive Care Med Exp. 2014;2(1):20.
7. Cazalis MA, Friggeri A, Cavé L, Demaret J, Barbalat V, Cerrato E, et al. Decreased HLA-DR antigen-associated invariant chain (CD74) mRNA expression predicts mortality after septic shock. Crit Care. 2013;17(6):R287.
8. Maslove DM, Wong HR. Gene expression profiling in sepsis: timing, tissue, and translational considerations. Trends Mol Med. 2014;20(4):204-13.
9. Pachot A, Lepape A, Vey S, Bienvenu J, Mougin B, Monneret G. Systemic transcriptional analysis in survivor and non-survivor septic shock patients: a preliminary study. Immunol Lett. 2006;106(1):63-71.
10. Pachot A, Cazalis MA, Venet F, Turrel F, Faudot C, Voirin N, et al. Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression. J Immunol. 2008;180(9):6421-9.
11. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101(6):1644-55.
12. Vincent JL, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet. 2013;381(9868):774-5.
13. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862-71.
14. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270(24):2957-63.
15. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med. 1998;26(11):1793-800.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
17. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007;8(2):R19.
18. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862-74.
19. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13(3):260-8.
20. Venet F, Lukaszewicz AC, Payen D, Hotchkiss R, Monneret G. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr Opin Immunol. 2013;25(4):477-83.
21. van der Poll T. Future of sepsis therapies. Crit Care. 2016;20(1):106.
22. Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007;317(5838):666-70.
23. Ishida Y, Hayashi T, Goto T, Kimura A, Akimoto S, Mukaida N, et al. Essential involvement of CX3CR1-mediated signals in the bactericidal host defense during septic peritonitis. J Immunol. 2008;181(6):4208-18.
24. Raspe C, Hocherl K, Rath S, Sauvant C, Bucher M. NF-kB-mediated inverse regulation of fractalkine and CX3CR1 during CLP-induced sepsis. Cytokine. 2013;61(1):97-103.
25. high monocytes protect against kidney damage during sepsis via a CX3CR1-dependent adhesion mechanism. J Am Soc Nephrol. 2016;27(3):792-803.
26. An JL, Ishida Y, Kimura A, Tsokos M, Kondo T. Immunohistochemical detection of CCR2 and CX3CR1 in sepsis-induced lung injury. Forensic Sci Int. 2009;192(1-3):e21-5.
27. Feezor RJ, Baker HV, Xiao W, Lee WA, Huber TS, Mindrinos M, et al. Genomic and proteomic determinants of outcome in patients undergoing thoracoabdominal aortic aneurysm repair. J Immunol. 2004;172(11):7103-9.
28. Hoogendijk AJ, Wiewel MA, van Vught LA, Scicluna BP, Belkasim-Bohoudi H, Horn J, et al. Plasma fractalkine is a sustained marker of disease severity and outcome in sepsis patients. Crit Care. 2015;19:412.
29. Johnson SB, Lissauer M, Bochicchio GV, Moore R, Cross AS, Scalea TM. Gene expression profiles differentiate between sterile SIRS and early sepsis. Ann Surg. 2007;245(4):611-21.
30. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301-5.
31. Sprung CL, Sakr Y, Vincent JL, Le Gall JR, Reinhart K, Ranieri VM, et al. An evaluation of systemic inflammatory response syndrome signs in the Sepsis Occurrence in Acutely ill Patients (SOAP) study. Intensive Care Med. 2006;32(3):421-7.
32. Dulhunty JM, Lipman J, Finfer S. Does severe non-infectious SIRS differ from severe sepsis? Results from a multi-centre Australian and New Zealand intensive care unit study. Intensive Care Med. 2008;34(9):1654-61.